No 10Y consistency score yet for revenue — the year-earlier revenue was zero, negative or too small a base to compare against in 20 of the 40 quarters in the window, leaving 20 comparable quarters; at least 28 are needed.
Valuation vs own 10Y history: P/S 604.4x · 10Y median 453.7x · 59th percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 40
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T22:04:26.704Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Alaunos Therapeutics, Inc. (TCRT) stock was $0.74 as of Oct 6, 2026, 4:00 PM EDT, down 6.65% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -68.8% · 3-year avg -63.6%/yr · 5-year avg -69.1%/yr
Alaunos Therapeutics, Inc. is an oncology company in the clinical trial phase, specializing in the creation of adoptive T-cell receptor (TCR) engineered therapies.
Biotechnology · Fort Lauderdale, FL
Next Earnings Date
Nov 17, 2026
42 days away
EPS Estimate
-15.75
Revenue Est.
N/A
Last Quarter Results
EPS
$-17.09
vs Estimate
$-4.50
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1TCRT | $1.81M | $0.74 | -6.65% | -68.76% | -69.13% | -50.22% | N/A |
| 2PFSA | $1.83M | $1.66 | -5.14% | -99.93% | N/A | N/A | vs TCRT |
| 3XAIR | $1.84M | $2.55 | -10.21% | -94.08% | -76.73% | N/A | vs TCRT |
| 4TNON | $1.84M | $3.71 | +0.41% | -91.30% | N/A | N/A | vs TCRT |
| 5RNAZ | $1.88M | $1.78 | +1.14% | -83.28% | -93.39% | N/A | vs TCRT |
| 6AMIX | $1.88M | $3.47 | -1.98% | -85.08% | N/A | N/A | vs TCRT |
forward FY estimate
N/A
$0.00
vs Estimate
N/A
Consensus Rating
No analyst recommendations available
Average Price Target
N/A
Low
N/A
Current
$0.74
High
N/A
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-15.75 | $-15.75 | $-15.75 | 1 |
| Quarter ending Dec 2026 | $-17.59 | $-17.59 | $-17.59 | 1 |
| Quarter ending Mar 2027 | $-18.86 | $-18.86 | $-18.86 | 1 |
| Quarter ending Jun 2027 | $-12.70 | $-12.70 | $-12.70 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-21.00 | $-21.00 | $-21.00 | 1 |
| FY 2027 | $-18.00 | $-18.00 | $-18.00 | 1 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Dec 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Mar 2027 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Jun 2027 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $87.53M | $87.53M | $87.53M | 1 |
| FY 2027 | $220.41M | $220.41M | $220.41M | 1 |
